NCT00287222View on ClinicalTrials.gov

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Bevacizumab

15 mg/KG I.V. every 21 days

DRUG

Erlotinib

150 mg orally every day

Trial Locations (2)

66160

Kansas University Medical Center, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Arkansas

OTHER